Reduced expression of the p53 family member p63 has been suggested to play a causative role in cancer metastasis. Here, we show that DNp63a, the predominant p63 isoform, plays a major role in regulation of cell migration, invasion and cancer metastasis. We identified mitogen-activated protein (MAP) kinase phosphatase 3 (MKP3) as a downstream target of DNp63a that is required for mediating these effects. We show that DNp63a regulates extracellular signal-regulated protein kinases 1 and 2 (Erk1/2) activity via MKP3 in both cancer and non-transformed cells. We further show that exogenous DNp63a inhibits cell invasion and is dependent on MKP3 upregulation for repression. Conversely, endogenous pan-p63 ablation results in increased cell migration and invasion, which can be reverted by reintroducing the DNp63a isoform alone, but not by other isoforms. Interestingly, these effects require Erk2, but not Erk1 expression, and can be rescued by enforced MKP3 expression. Moreover, MKP3 expression is reduced in invasive cancers, and reduced p63 expression increases metastatic frequency in vivo. Taken together, these results suggest an important role for DNp63a in preventing cancer metastasis by inhibition of Erk2 signaling via MKP3.
INTRODUCTION
The p63 gene is expressed from two different promoters that generate isoforms either with a p53-homologous transactivation domain (TAp63) or without this domain (DNp63). In addition, alternative splicing gives rise to three different C-termini (a, b and g), for a total of six isoforms. The DNA-binding and oligomerization domains are shared by all isoforms and are highly homologous to those of p53. Further, p63a isoforms contain a sterile alpha motif, important for protein-protein interactions, and a post-inhibitory domain for intramolecular inhibition of gene transactivation. 1-3 p63 has been shown to possess pleiotropic functions, including regulation of cell proliferation, survival, apoptosis, differentiation, senescence and aging. 4, 5 Mutations in the p63 gene have been associated with human autosomal dominant developmental diseases affecting primarily the skin and orofacial and limb morphogenesis, including ectrodactyly ectodermal dysplasia-cleft lip/palate syndrome and ankyloblepharon-ectodermal dysplasiaclefting syndrome. 6, 7 Mice lacking all p63 isoforms exhibit early post-natal lethality and severe developmental defects, including a complete lack of all stratified epithelia and ectodermal appendages, severe craniofacial defects and limb truncation. 8, 9 It has been shown that p63 is essential for epithelial stem cell maintenance and epithelial differentiation. 10, 11 In addition, p63 deficiency leads to increased cellular senescence and an aging phenotype in mice. 12 A role for p63 in cancer development is demonstrated by a genetic study in which p63 haploinsufficiency in p53 þ / À mice markedly increases metastatic frequency. 13 Further studies show that TAp63 þ / À and TAp63 À / À mice develop spontaneous carcinomas and sarcomas that are highly metastatic. 14 Moreover, TAp63 specifically functions in the female germline to protect genomic integrity. 15, 16 DNp63a is the predominant p63 isoform expressed in basal epithelial cells and is essential for epithelial development. 3, 17 DNp63a regulates the expression of several adhesion molecules, including integrins b1, b4 and a6, and the demosome protein PERP, 18, 19 which implicates it in cell invasion. Loss of DNp63a expression results in cell detachment and anoikis, 18 whereas expression of DNp63a inhibits TAp73-mediated apoptosis. 20, 21 In line with these observations, DNp63a cooperates with Ras to promote skin stem cell proliferation and tumorigenesis. 22 Furthermore, DNp63a is frequently overexpressed in low-grade squamous cell carcinoma (SCC). [23] [24] [25] On the other hand, reduced p63 expression is associated with progression in a variety of cancers, including esophageal SCC, prostate cancer and melanoma. [26] [27] [28] Together, these data suggest that DNp63a may promote early stages of tumor development, but acts to inhibit cancer metastasis.
However, little is known about the molecular effects by which DNp63a, the predominant p63 isoform in cancer cells, affects tumor progression. Here, using breast cancer models, we uncovered an unexpected link to extracellular signal-regulated protein kinases 1 and 2 (Erk1/2). Sustained Erk1/2 activity promotes tumorigenesis by inducing cell growth and proliferation, and it is often upregulated in advanced cancers. [29] [30] [31] Moreover, invasive cancer cells have higher Erk1/2 activity, 32 which drives cell migration, invasion and metastasis. [33] [34] [35] Mitogen-activated protein (MAP) kinase phosphatase 3 (MKP3; also known as DUSP6 or Pyst1) specifically dephosphorylates Erk1/2, thus restraining signal strength and duration, and acting as a putative tumor suppressor. 36, 37 In this study, based on microarray analyses, we uncovered that unlike TAp63 isoforms, DNp63a directly activates transcription of MKP3, leading to specific regulation of Erk2 signaling. Thus, we demonstrate that the DNp63a isoform plays a critical role in inhibiting cancer cell migration, invasion and metastasis via a novel signaling mechanism that engages the Erk pathway.
RESULTS

DNp63a upregulates MKP3 expression
To identify DNp63a downstream targets through which DNp63a executes its biological functions, we profiled gene expression of cells expressing wild-type DNp63a in comparison with that of cells expressing mutant derivatives or a vector control using Affymetrix gene chip analysis. Accordingly, we stably expressed wild-type or mutant DNp63a in human breast cancer Hs-578T cells. These cells are highly invasive but not tumorigenic, 38 and have no detectable p63 protein expression. The C306R mutation maps to the DNAbinding domain and is associated with ectrodactyly ectodermal dysplasia-cleft lip/palate syndrome, whereas the C526W mutation is associated with ankyloblepharon-ectodermal dysplasia-clefting syndrome and is located in the sterile alpha motif domain, thus affecting p63a isoforms exclusively. 6, 7 On analysis of the microarray, we observed that MKP3 gene expression was upregulated by wild-type DNp63a to a much greater extent than by the mutant derivatives ( Figure 1a ). This conclusion was validated by quantitative PCR (Q-PCR) analysis ( Figure 1b ) and western blotting ( Figure 1c ).
To explore the clinical relevance of p63-mediated regulation of MKP3 in cancer development, we analyzed the online microarray database Oncomine, and observed a clear correlation between decreased p63 and MKP3 gene expression and cancer progression in human cancer specimens. Figure 1d showed that expression of both p63 and MKP3 is decreased in invasive ductal breast carcinoma, compared with normal breast tissue, 39 and Figure 1e showed similar results using a different data set. These observations implicate a clear correlation between downregulation of p63 and MKP3 and breast cancer progression.
DNp63a modulates Erk1/2 signaling As MKP3 is an important negative regulator of Erk1/2, we reasoned that DNp63a might regulate Erk1/2 signaling through its modulation of MKP3 expression. To test this hypothesis, we stably expressed DNp63a in MDA-MB-231 cells, a highly invasive and tumorigenic human breast cancer cell line with no detectable p63 protein expression. Consistent with our previous results, DNp63a significantly upregulated MKP3 expression at both the mRNA and protein levels (Figures 2a and b ). Elevated MKP3, however, did not significantly result in downregulation of Erk1/2 protein phosphorylation ( Figure 2b ). This was likely due to the presence of hyper-activated Ras(G13D) and Raf(I326T) mutations in MDA-MB-231 cells, 40 which overpower the effects of MKP3 on Erk1/2 phosphorylation. As MKP3 can inhibit Erk1/2 translocation to the nucleus, 41 we investigated whether DNp63a affects the intracellular distribution of phosphorylated Erk1/2. We immunostained for p63 protein and for phosphorylated Erk1/2 in MDA-MB-231 cells with or without stable expression of DNp63a. Strikingly, cells that lacked DNp63a expression exhibited strong nuclear phosphorylated Erk1/2 (arrows, Figure 2c ), whereas cells with DNp63a expression showed a uniform distribution of Erk1/2 phosphorylation between the cytosol and the nucleus. Indeed, approximately 40% of DNp63a-negative cells exhibited strong staining of nuclear Erk1/2 phosphorylation, whereas o15% of DNp63a-positive cells showed a similar pattern ( Figure 2d ). In addition, cellular fractionation experiments showed that DNp63a expression resulted in decreased phosphorylated Erk1/2 in the nuclear fraction, as we expected, whereas no significant changes were observed in the much more abundant cytosolic fraction of phosphorylated Erk1/2 (Figure 2e ). Furthermore, the expression of two well-established Erk1/2 transcriptional targets, matrix metalloproteinase 1 (MMP1) and MMP9, 42, 43 was markedly decreased on DNp63a expression ( Figure 2f ). Accordingly, MMP1 and MMP9 expression is decreased in human invasive breast cancer biopsies, as assessed by Oncomine (Supplementary Figure S1a ). Together, these data indicate that DNp63a negatively regulates Erk1/2 signaling via MKP3.
DNp63a inhibits cell invasion in an MKP3-dependent manner It is well documented that Erk1/2 dysregulation causatively promotes cell migration, invasion and cancer metastasis. [33] [34] [35] We therefore asked whether DNp63a expression inhibits Erk1/2 and inhibits cancer cell invasion. As shown in Figures 3a and b , expression of DNp63a in MDA-MB-231 cells significantly reduced cell invasion. We next examined whether DNp63a-mediated MKP3 induction is responsible for these effects. Again, DNp63a significantly reduced MDA-MB-231 cell invasion, which was significantly reversed by simultaneous MKP3 knockdown using specific short hairpin RNAs (shRNAs; Figures 3c-e, and Supplementary Figure S1b ). Furthermore, MKP3 ablation restored MMP1 and MMP9 expression in MDA-MB-231 cells expressing DNp63a, as assessed by Q-PCR ( Figure 3f ). Together, these results indicate that DNp63a-mediated MKP3 modulation is an important mechanism for regulating cancer cell invasion. Figure S2b ), whereas no significant changes in total Erk1/2 protein or Mek phosphorylation levels were observed ( Figure 4b ).
In order to further investigate the molecular mechanism by which DNp63a regulates MKP3 expression, we asked whether DNp63a directly binds to the promoter of the MKP3 gene. Computational analysis of the human MKP3 gene and promoter revealed several potential p63/p53-binding sites, including a putative p63-binding site located 141-bp upstream from the translational start site ( Figure 4c ). Chromatin immunoprecipitation using a specific p63 antibody showed direct binding of p63 to this site ( Figure 4d ), suggesting that DNp63a exerts direct transcriptional regulation on MKP3. Consistently, knockdown of p63 resulted in marked increases in MMP1 and MMP9 expression in both MCF-10A and FaDu cells ( Figure 4e ). Taken together, these findings indicate that MKP3 is a direct DNp63a transcriptional target, and that DNp63a negatively regulates Erk1/2 activity via MKP3. p63 ablation enhances cell migration and invasion Next, we investigated the biological consequences of p63mediated modulation of Erk1/2 activity, focusing on cell migration and invasion. Knockdown of all p63 isoforms in MCF-10A and FaDu cells led to a dramatic increase in cell migration and invasion p63 inhibits cancer metastasis via MKP3 J Bergholz et al (Figures 5a and b ). In addition, p63 knockdown in MCF-10A cells resulted in a morphological change from cuboidal and cobblestone-like to elongated and spindle-like morphology (Supplementary Figure S2d ). To study the underlying mechanism by which p63 modulates cell migration, we examined the distribution of focal adhesions by immunostaining for phosphopaxillin, a component of the focal adhesion complex. It has been shown that large focal adhesions orderly assembled around the periphery of the cells are indicative of low cell motility because of poor turnover of the focal adhesion complex. 44, 45 As shown in Figure 5c , although control MCF-10A cells exhibited a normal staining pattern of large focal adhesions around the periphery, knockdown of p63 in these cells led to a punctuated and disorganized pattern of small focal adhesions, indicative of increased turnover and enhanced motility.
To investigate whether a particular p63 isoform(s) specifically mediates these effects, we introduced Myc-tagged murine DNp63a, DNp63g, TAp63a or TAp63g into MCF-10A cells that were ablated for endogenous p63, followed by western blot analysis ( Figure 5d Figure S3b) , completely restored the non-invasive phenotype (Figure 6a ). Accordingly, U0126 treatment clearly inhibited MMP1 and MMP9 upregulation elicited by p63 knockdown in MCF-10A cells (Supplementary Figure S3c) .
As Erk1 and Erk2 possess similar biochemical activities, we studied the effect of Erk1 or Erk2-specific ablation on p63 knockdown in MCF-10A cells (Figure 6b) . Surprisingly, knockdown of Erk1 had little effect on cell invasion. In sharp contrast, knockdown of Erk2 alone significantly reduced invasion of p63deficient cells (Figure 6c and Supplementary Figure S3d ). Notably, simultaneous knockdown of Erk1 and Erk2 did not reduce cell invasion further, compared with Erk2 knockdown alone.
We then examined focal adhesions by immunostaining for phospho-paxillin. The p63-deficient cells again exhibited a punctuated, disorganized pattern of focal adhesions. Knockdown of Erk2 in these cells led to formation of large focal adhesions organized around the periphery of the cell, similar to those of the control cells ( Figure 6d ). On the other hand, knockdown of Erk1 did not affect focal adhesion patterns observed in either the control cells or in cells (Figure 6d ). Together, these results show that DNp63a-mediated modulation of focal adhesions and cell migration/invasion is dependent on Erk2, but not on Erk1.
Next, we studied the role of MKP3 in p63-mediated regulation of cell motility. In line with our previous results, ablation of MKP3 in MCF-10A cells led to an increase in MMP1 expression and to a much higher level of MMP9 expression (Supplementary Figure  S4a ). Knockdown of p63 in MCF-10A cells reproducibly led to increased cell migration and invasion, concomitant with a reduction in MKP3 protein expression and increased Erk1/2 phosphorylation (Figure 7) . Importantly, exogenous expression of MKP3 in these cells (Figure 7a Figure S4b ). In addition, MKP3 overexpression in p63-ablated MCF-10A cells also restored focal adhesion organization back to large complexes orderly arranged around the periphery of the cells (Figure 7d ). These data strongly support an important role for MKP3 in negative regulation of cell migration and invasion.
Reduced p63 expression enhances metastasis in vivo
We further investigated the pathological role of reduced DNp63a expression in breast cancer metastasis. We chose to use MCF-10A cells because they express abundant endogenous DNp63a protein, yet they are non-tumorigenic. However, MCF-10A cells expressing hyperactive murine Her2/Neu (V664E; referred to as NeuT) are tumorigenic in a nude mouse model, as we have shown previously. 46 Thus, we transformed MCF-10A cells by stable transfection with NeuT. These cells exhibited neoplastic phenotypes, including loss of contact inhibition and formation Figure S5a) . Notably, p63 knockdown in NeuT-expressing cells (NeuT-shp63) resulted in increased cell invasion, compared with NeuT cells expressing a control shRNA (NeuT-shC) ( Supplementary Figures  S4b and S4c ). We then injected MCF-10A-NeuT cells with or without p63 ablation into the lateral tail vein of recipient nude mice, an established lung metastasis model. 44 Forty-five days after injection, mice were euthanized and their lungs dissected and inspected for metastatic nodules (Figure 8a ). Three out of five mice injected with NeuT-shp63 cells exhibited three, four and five large metastatic nodules each, visible on the surface of the lungs, whereas only one out of six mice injected with NeuT-shC cells formed just one observable metastatic nodule (Figure 8b) .
Furthermore, histological analysis demonstrated normal lung architecture in the majority of the control mice, whereas lungs from mice injected with NeuT-shp63 cells showed frequent infiltration of metastatic cells (Figure 8c ). Taken together, these results highlight the importance of DNp63a reduction as an important factor in promoting metastasis in vivo.
DISCUSSION
In this study, we demonstrated that the major protein isoform of p63, DNp63a, plays a critical role in modulation of cell migration and invasion, as well as cancer metastasis, in an Erk2-dependent pathway. First, exogenous expression of wild-type DNp63a, but Figure 5 . DNp63a, but not other p63 isoforms, inhibits cell migration and invasion. (a, b) MCF-10A and FaDu cells stably expressing shRNA specific for pan-p63 (shp63) or green fluorescent protein (GFP) (shC) were subjected to cell migration (a) or invasion assays (b), using transwell systems. Migratory and invasive cells were fixed and stained with crystal violet and quantitated as described in the Materials and methods section. Results are presented as means and s.e. from three experiments. (c) MCF-10A cells infected with recombinant lentivirus encoding shRNA specific for p63 (shp63) or GFP as a control (shC) were grown in fresh normal growth media (see Materials and methods section) for 2 h before fixation. Cells were then immunostained for phospho-paxillin (pTyr118) and counterstained with 4,6-diamidino-2-phenylindole (DAPI). A representative figure from two independent experiments performed in triplicate is shown. Note the punctuated staining of focal adhesion complexes in p63-ablated cells in contrast to the organized peripheral staining in control cells (insets). Scale bars ¼ 20 mm. (d, e) MCF-10A cells infected with recombinant lentivirus encoding shRNA specific for p63 (shp63) or GFP as a control (shC) were transiently transfected with mouse Myc-tagged DNp63a, DNp63g, TAp63a, TAp63g or a vector control (V) as shown. Cells were subjected to western blotting (d) or to invasion assays using transwell systems (e). Results are presented as means and s.e. from two independent experiments. *Po0.05; **Po0.01.
not of the disease-associated mutant derivatives, inhibits cancer cell invasion. Second, DNp63a transcriptionally upregulates MKP3, which in turn inhibits Erk1/2 signaling and reduces cell motility. Third, knockdown of p63 promotes cell migration and invasion, which is effectively rescued by expression of MKP3 or DNp63a, but not by DNp63g or TAp63 isoforms. Fourth, knockdown of p63 facilitates turnover of focal adhesions and cell invasion, which is overcome by ablation of Erk2, but not Erk1. Furthermore, reduction of p63 markedly enhances metastasis in a lung metastasis model, which is reminiscent of clinical observations in which expression of both p63 and MKP3 are inversely correlated with cancer progression. 47 Here, we reproducibly observe punctuated, small focal adhesions on p63 ablation, concomitant with increased Erk1/2 activity. These data are consistent with the notion that reduction of DNp63a stimulates Erk1/2 activity and promotes cell migration. Interestingly, it has been shown that Erk2 is responsible for Rasinduced epithelial-to-mesenchymal transition and increased cell migration and invasion. 48 Our data show that reduction of only Erk2, but not Erk1, effectively reverses p63 ablation-induced cell migration. These studies suggest that Erk2 is a major effector that integrates a variety of different signals in regulation of cell migration. It is plausible that Erk2 specifically phosphorylates components of the focal adhesion complex to impact its turnover.
In addition to migration, Erk1/2 can also promote cell invasion by transcriptional upregulation of genes involved in cell invasion, such as MMP1, MMP2 and MMP9. 42, 43, 49 Our gain-and loss-offunction experiments demonstrate that DNp63a modulates Erk1/2 activity via MKP3, which in turn regulates MMP1 and MMP9 expression. Hence, reduced DNp63a expression leads to upregulation of MMP1 and MMP9, thereby promoting cell invasion. Interestingly, it has been shown that DNp63a can induce transcription of Id-3, which then inhibits Ets-1-mediated MMP2 gene expression and cell invasion. 50 Notably, Erk1/2 can phosphorylate and activate Ets-1 to stimulate MMP1 and MMP9 gene expression and cell invasion. 42, 43 Therefore, it is likely that DNp63a regulates cell invasion via direct modulation of Erk1/2 activity. It has been reported, however, that p53 can indirectly impact transcription of MMP1 and MMP9 via various transcriptional factors such as AP-1 and nuclear factor-kB. 51, 52 Although our data strongly suggest that DNp63a modulates MMP1 and MMP9 gene expression via Erk1/2, we cannot rule out the possibility that DNp63a may also modulate MMP1 and MMP9 expression via different mechanisms. Furthermore, Fukushima et al. 53 reported that loss of DNp63a in certain urothelial carcinoma cell lines results in increased N-Cadherin expression, leading to increased Erk1/2 signaling. In this study using mammary epithelial or head and neck SCC systems, we did not detect any significant changes in N-Cadherin expression. It remains possible that DNp63a modulates Erk1/2 activity by different mechanisms in a cell context-dependent manner.
Erk1/2 activity is tightly controlled spatially and temporally. Aberrant Erk1/2 activity in advanced cancers has often been linked to upregulated Ras and/or Raf signaling or increased receptor tyrosine kinase activity. 54 However, accumulating evidence indicate that dephosphorylation plays an equally important role for regulation of Erk1/2 activity. [55] [56] [57] MKP3 specifically dephosphorylates both the threonine and tyrosine residues in the activation loop of Erk1/2, an important mechanisms for restraining Erk1/2 activity. 58 In this study, we demonstrate that DNp63a regulates Erk1/2 activity in an MKP3-dependent manner. We show that DNp63a upregulates MKP3 expression leading to inhibition of cell invasion, which is markedly rescued by ablation of MKP3. Notably, knockdown of p63 induces cell invasion, which is fully reverted by ectopic expression of MKP3, yet p63 ablationinduced cell migration is only partially reverted by MKP3. These results suggest that MKP3 is a critical player in p63-mediated modulation of cell invasion, whereas additional factors are important for p63-mediated regulation of cell migration. Activation of Erk1/2 because of p63 ablation could arise from activation of upstream kinases in the MAP kinase cascade. However, despite repeated efforts, we did not detect significant changes in Mek phosphorylation, suggesting that p63 modulates Erk1/2 activity via MKP3, rather than by enhancing upstream kinase activity.
The two major p63 isoforms, TAp63 and DNp63, have been shown to execute overlapping as well as distinct biological functions. Recently, Flores et al. 14 showed that TAp63 suppresses metastasis through coordinate regulation of Dicer and miR-130b. 14 Our study demonstrates that DNp63a impacts the Erk1/ 2 pathway, leading to inhibition of cell migration and invasion, in accordance with the observations that reduced DNp63a expression upregulates genes involved in cell motility and induces cell invasion in SCC and keratinocyte cell lines. [59] [60] [61] Thus, both TAp63 and DNp63 function to inhibit metastasis likely through different mechanisms.
In this study, we show that two human disease-associated mutations in DNp63a, C304R in the DNA-binding domain and C526W in the sterile alpha motif domain, do not upregulate MKP3, and can not affect cell migration and invasion (unpublished data). These observations highlight the importance of DNA-binding activity and protein-protein interaction via the sterile alpha motif domain for the function of DNp63a in regulation of cell motility. Our data also show that, unlike DNp63a, DNp63g is unable to rescue MCF-10A cell invasion elicited by p63 ablation. Notably, it was reported that ablation of p63a and p63b, but leaving p63g expression intact, resulted in much increased cell invasion, compared with pan-p63 knockdown, 62 suggesting that DNp63g might promote cell invasion. Although we have not observed these effects of DNp63g in our system, it might be possible that the level of expression and the ratio between different p63 isoforms affect the results observed.
More recently, it has been shown that mutant p53 (mtp53) promotes metastasis through inhibition of p63. Piccolo et al. 63 show that mtp53 inhibits the anti-metastatic activity of p63 by forming a trimeric complex between mtp53, Smad2 and p63 on transforming growth factor-b stimulation. In addition, Vousden et al. 64 show that expression of mtp53 (R175H or R273H) in p53 null H1299 cells results in increased invasion, which can be reversed by TAp63a expression, suggesting that mtp53 suppresses endogenous TAp63 to promote cell invasion. In this study, we observe that inhibition of DNp63a in MCF-10A and FaDu cells increases migration and invasion. Importantly, MCF-10A cells express wild-type p53, whereas FaDu cells express truncated p53 from one allele and DNA-binding mutant (p53-R248L) from the other allele. 65 Thus, the ability of DNp63a to suppress migration and invasion is likely independent of p53. However, it remains possible that reduced p63 may cooperate with mtp53 to promote cell migration/invasion. Clearly, the interplay between different p63 isoforms, mutant p53 proteins, and p53 family members can largely determine the overall anti-metastatic activity.
Here, we uncovered that the DNp63a-MKP3-Erk2 pathway is an important mechanism in controlling cell migration and invasion. Whether this axis represents a true physiological pathway in vivo and whether dysregulation of this pathway is pathologically relevant are critical questions. It is well documented that activation of Erk1/2 is a causative factor for cancer progression and metastasis. 32 Accumulating evidence clearly indicate a clinical correlation between reduction of p63 and/or MKP3 expression and cancer progression, including SCC, breast, lung and pancreatic cancers. [26] [27] [28] 39, 56, 57, 66 Interestingly, in human head and neck SCC where DNp63a is often overexpressed, expression of MKP3 is also increased. 67, 68 Furthermore, using an established lung metastasis model, we show that reduction of p63 significantly increases metastasis in mice. Notably, Her2/Neu can transform MCF-10A cells and promotes rapid tumor formation in nude mice, yet these tumors exhibit limited metastatic potential. 46 Interestingly, we showed that knockdown of p63 significantly enhances the metastatic potential of these cells, indicating that reduction of DNp63a greatly potentiates Her2-mediated malignant activity. Altogether, this study demonstrates that dysregulation of the DNp63a-MKP3-Erk2 pathway is important for cancer metastasis. Further studies will be necessary to decipher the specific contribution from each p63 isoform and their interactions with other p53 family members so as to develop strategies for more efficacious treatments and preventions against cancer metastasis.
MATERIALS AND METHODS
Cell culture
Human non-transformed mammary epithelial MCF-10A cells were maintained in Dulbecco's modified Eagle's medium (DMEM):F12 media (1:1 mixture of DMEM and Ham's F12 medium with reduced Ca 2 þ (0.04 mM; Invitrogen Inc., Carlsbad, CA, USA)), supplemented with 20 ng/ml epidermal growth factor (Invitrogen Inc.), 100 ng/ml cholera toxin (Sigma, St Louis, MO), 10 mg/ml insulin (Sigma), 500 ng/ml (95%) hydrocortisone (Sigma) and 5% of Chelex-treated horse serum (Invitrogen Inc.). Human head and neck SCC FaDu cells, human breast cancer MDA-MB-231 cells and HEK-293T cells were maintained in DMEM supplemented with 10% fetal bovine serum (Invitrogen Inc.). Human breast cancer Hs-578T cells were cultured in DMEM supplemented with 10% fetal bovine serum and 10 mg/ml of insulin. All cells were grown in media supplemented with 1% L-glutamine and 1% penicillin-G/streptomycin sulfate at 37 1C in a humidified incubator under 5% CO 2 .
Plasmid transfections, viral infections and RNA interference
Transient transfections were carried out using Lipofectamine 2000 (Invitrogen Inc.). Expression plasmids include myc-tagged murine pcDNA3-DNp63a, pcDNA3-DNp63g, pcDNA3-TAp63a and pcDNA3-TAp63g, murine pMSCVpuro-DNp63a and human myc-tagged pSG5-MKP3. Retrovirus were amplified by transfecting HEK-293T cells with 3 mg each of Gag/Pol and Env packaging plasmids and the retroviral expression plasmid using Lipofectamine 2000. Lentivirus were amplified by transfecting HEK-293T cells with 1.2 mg each of Gag/Pol, Tat and Env, 2.4 mg Vsv-g packaging plasmids, and 24 mg of the lentiviral expression plasmid using TransIT (Mirus, Madison, WI, USA). Lentiviral-based shRNA against green fluorescent protein, human p63, Erk1 and Erk2 in pLKO.1puro backbones were obtained from Thermo Fisher Scientific (Waltham, MA, USA). The shRNA against human MKP3 is in a pSICOR(puro) plasmid.
Western blot analysis and immunofluorescence
Cells were lysed in EBC 250 lysis buffer. 69 Nuclear extraction was performed with cytoskeletal buffer (10 mM PIPES (pH 6.8), 100 mM NaCl, 300 mM sucrose, 3 mM MgCl 2 , 1 mM EGTA, 1 mM DTT, 10 mM NaF, 0.1% Triton X-100, 1 mM ATP). Proteins were resolved by sodium dodecyl sulfatepolyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membranes (NEN LifeSciences, Waltham, MA, USA) and hybridized to an appropriate primary antibody and horseradish peroxidase (HRP)-conjugated secondary antibody for subsequent detection by enhanced chemiluminescence (Thermo Fisher Scientific Inc., Rockford, IL, USA). For immunostaining, cells grown on coverslips were fixed with 3.7% formaldehyde in phosphate-buffered saline (PBS), permeabilized with 0.1% Triton X-100 in PBS, blocked with 1% bovine serum albumin in PBS, and sequentially incubated with primary and secondary antibodies prepared in 4% bovine serum albumin. Coverslips were mounted with ProLong Gold antifade reagent with 4,6-diamidino-2-phenylindole (Invitrogen Inc.). Using an Axiovert 200 M microscope (Carl Zeiss, Oberkochen, Germany) under 40 Â or 100 Â objective lenses, fluorescent images were acquired using an AxioCam MRm (Carl Zeiss) and processed with AxioVision 4 software (Carl Zeiss). Monoclonal antibody specific for p63 (4A4) and goat anti-actin antibody (C-11) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit anti-MKP3 (3058), rabbit antiphospho-Erk1/2 (9109), rabbit anti-Erk1/2 (9102), rabbit anti-phospho-Mek (9121), rabbit anti-Mek (9122) and rabbit anti-phospho-paxillin (pTyr118; 2541) antibodies were purchased from Cell Signaling (Danvers, MA, USA). Goat anti-mouse immunoglobulin G-HRP (sc-2005), goat anti-rabbit immunoglobulin G-HRP (sc-2004) and donkey anti-goat immunoglobulin G-HRP (sc-2020) secondary antibodies for western blotting were obtained from Santa Cruz Biotechnology. Secondary antibodies used for immunostaining, including goat anti-mouse Alexa Fluor 488 (A11001), goat antirabbit Alexa Fluor 488 (A11008) and goat anti-rabbit Alexa Fluor 594 (A11012), were purchased from Invitrogen Inc.
Affymetrix array and Q-PCR analysis
Total RNA was isolated using TRIzol (Gibco Life Technologies, Rockville, MD, USA) or RNeasy Mini Kit (Qiagen, Chatsworth, CA, USA), followed by reverse transcription using SuperScript III First-Strand Synthesis System (Invitrogen Inc.). Array analysis was performed using U133Av2.0 human gene chip (Affymetrix, Santa Clara, CA, USA) in two independent experiments. Q-PCR was performed in a 7300 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) using QuantiTect SYBR Green PCR Kit (Qiagen) according to the manufacturer's instructions. Primers used for Q-PCR are listed in Supplementary Table S1 in the Supplementary Material.
Assays for cell migration and invasion
Cell migration was measured using 6.5 mm, 8.0 mm-pore polycarbonate membrane transwell inserts (BD Biosciences, San Jose, CA, USA). Cell invasion was measured using matrigel-coated inserts (BD Biosciences). Cells (1.0 Â 10 5 to 2.5 Â 10 5 ) were suspended in serum-free DMEM (for MDA-MB-231 and FaDu cells) or DMEM:F12 (for MCF-10A cells) media containing 0.5% gelatin and seeded into the inner chamber. The outer chamber was filled with normal growth media (as described previously for each cell type) containing 0.5% gelatin. Cells were incubated for 16-24 h. Non-migrating cells were carefully removed with a cotton swab. Migrating cells were stained with 0.5% crystal violet in 70% ethanol for 10 min at room temperature, and photographed under a Zeiss light microscope. At least 100 cells in total from five random fields were counted. Alternatively, the stained cells were lyzed with 2% sodium dodecyl sulfate in PBS and subjected to spectrophotometric analysis at 570 nm.
In vivo metastasis assays MCF-10A cells were infected with pBABE-NeuT or pBABE. Puromycinresistant cells were then infected with lentivirus expressing shRNA against p63 (NeuT-shp63) or green fluorescent protein (NeuT-shC). 1.0 Â 10 6 NeuT-shC or NeuT-shp63 cells in 200 ml PBS were injected into the lateral tail vein of six NCr nude six-week-old female mice (CrTac:NCr-Foxn1 nu ; Taconic, Hudson, NY, USA). Mice were observed daily and euthanized after 45 days. During the course of the experiment, one NeuT-shp63 mouse died for reasons unclear. The lungs were dissected and inspected for metastatic nodules. Lungs were then fixed overnight in 3.7% formaldehyde, embedded in paraffin and sectioned onto microscope slides for hematoxylin and eosin (H&E) staining and histological analysis. All animal studies were approved by the Institutional Animal Care and Use Committee.
Statistical analysis
Quantitative data were analyzed statistically using Student's t-test to assess significance. Data are presented as means±s.e., as noted on figure legends.
Bioinformatic analysis of gene expression
Oncomine (Compendia Bioscience, Ann Arbor, MI, USA) was used for analysis and visualization.
